BiotechTube

Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Primary Immune Deficiency Disorders (PIDD)

Conditions

Primary Immune Deficiency Disorders (PIDD)

Trial Timeline

Sep 1, 2007 → Jul 1, 2009

NCT ID
NCT00538915

About Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]

Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%] is a phase 3 stage product being developed by ADMA Biologics for Primary Immune Deficiency Disorders (PIDD). The current trial status is completed. This product is registered under clinical trial identifier NCT00538915. Target conditions include Primary Immune Deficiency Disorders (PIDD).

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00538915Phase 3Completed

Competing Products

20 competing products in Primary Immune Deficiency Disorders (PIDD)

See all competitors
ProductCompanyStageHype Score
Unfractionated heparinSinopharmPre-clinical
22
azenosertibZentalis PharmaceuticalsPhase 2
44
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
77
REN001OnKure TherapeuticsPhase 1
25
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
44
REN001OnKure TherapeuticsPhase 2/3
57
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
44
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
52
Rituximab, lenalidomideCelltrionPhase 2
52
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
77
CS-3150Daiichi SankyoPre-clinical
23
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPre-clinical
23
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
85
Combination of bempedoic acid and ezetimibeDaiichi SankyoPre-clinical
23
DS-8201a + T-DM1Daiichi SankyoPhase 3
77
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
23
Roxadustat + PlaceboAstellas PharmaPhase 3
77
Enzalutamide + ExemestaneAstellas PharmaPhase 2
52
Bocidelpar + PlaceboAstellas PharmaPhase 2
52
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
52

Other Products from ADMA Biologics

Asceniv™Approved
80
BivigamApproved
80
RI-002Phase 3
72
RI-001 + RI-001 + RI-001Phase 2
47
Hepatitis C Immune Globulin Intravenous (Human) 5%Phase 2
47